Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Exelixis, Inc. (EXEL)

22.19   0.44 (2.02%) 09-27 16:00
Open: 21.81 Pre. Close: 21.75
High: 22.19 Low: 21.79
Volume: 2,006,525 Market Cap: 7,065(M)

Technical analysis

as of: 2023-09-27 4:19:11 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 26.63     One year: 31.1
Support: Support1: 21.87    Support2: 21.29
Resistance: Resistance1: 22.79    Resistance2: 26.63
Pivot: 21.83
Moving Average: MA(5): 21.76     MA(20): 21.98
MA(100): 20.25     MA(250): 18.43
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 52.8     %D(3): 35
RSI: RSI(14): 59.4
52-week: High: 22.79  Low: 14.86
Average Vol(K): 3-Month: 2,223 (K)  10-Days: 2,440 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ EXEL ] has closed below upper band by 20.4%. Bollinger Bands are 11% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 22.15 - 22.26 22.26 - 22.35
Low: 21.48 - 21.6 21.6 - 21.7
Close: 21.58 - 21.76 21.76 - 21.91

Company Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Headline News

Wed, 27 Sep 2023
Exelixis Inc (EXEL) Stock: How Does it Score on Valuation Metrics? - InvestorsObserver

Tue, 26 Sep 2023
Guggenheim Maintains Exelixis (EXEL) Buy Recommendation - Nasdaq

Mon, 25 Sep 2023
BMRN: 3 Biotech Stocks Offering Potential for Gains -

Sun, 24 Sep 2023
HB Wealth Management LLC Sells 5683 Shares of Exelixis, Inc ... - MarketBeat

Fri, 22 Sep 2023
Exelixis, Inc. (NASDAQ:EXEL) Stock Position Lowered by Nordea ... - MarketBeat

Thu, 14 Sep 2023
Stifel Reiterates Exelixis (EXEL) Hold Recommendation - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 318 (M)
Shares Float 287 (M)
% Held by Insiders 1.9 (%)
% Held by Institutions 89 (%)
Shares Short 7,880 (K)
Shares Short P.Month 6,420 (K)

Stock Financials

EPS 0.5
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.88
Profit Margin (%) 9.5
Operating Margin (%) 8.2
Return on Assets (ttm) 2.9
Return on Equity (ttm) 6.6
Qtrly Rev. Growth 12
Gross Profit (p.s.) 4.86
Sales Per Share 5.37
EBITDA (p.s.) 0.52
Qtrly Earnings Growth 13.6
Operating Cash Flow 389 (M)
Levered Free Cash Flow 69 (M)

Stock Valuations

PE Ratio 44.38
PEG Ratio 0.6
Price to Book value 2.81
Price to Sales 4.13
Price to Cash Flow 18.15

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.